Did you know that there is no official source for case counts broken out by age AND state? CDC reports only national data. And good luck trying to assemble this dataset from individual states. States don’t use the same age cut points! https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
Follow Friday: “Ladies I’m learning a lot from” Edition @SaskiaPopescu infection control @uche_blackstock health equity @meganranney get her PPE @devisridhar global health @mugecevik medical virology @cmyeaton outbreak science @BhadeliaMD ID clinician @JuliaLMarcus harm reduction
This quote from one of the authors of the airborne transmission study in PNAS bugs me. Scientific criticism is not less legitimate because it is posted on Twitter. https://www.buzzfeednews.com/article/peteraldhous/mario-molina-coronavirus-face-masks-pnas
In our continuous search for metrics to track, I’d like to see more discussion of median age of new diagnoses. Lower median age suggests: (1) we are better protecting the elderly, (2) we are testing enough to capture infections in the age range most likely to be missed.
I talked with @aaronecarroll about meeting the new baby in the time of corona. As a mom to a 6 month old, I understand the decisions families are navigating. With @gregggonsalves and @cmyeaton.
Aaron E. Carroll (@aaronecarroll):
When Can Grandparents Meet the Newborn? https://t.co/LclxpgAUaQ
Indeed an adaptive platform treatment trial in the US was the plan. The language is visible in the clinical trials registration. But was anyone in the trial randomized to anything besides remdesivir? Anyone know the status? https://clinicaltrials.gov/ct2/show/NCT04280705
Vinay Prasad (@VPrasadMDMPH):
In the US, had we committed to running multiarm randomized trials, we would have beaten the UK in answering the steroid question by weeks (Due to the larger sample size), saving many more lives
The next @Plenary_Session will be a hot take
Hey Twitter, show me your best Zoom backgrounds.
From fellow @HarvardBiostats alum Sarah Anoke: “Colleagues say to you ‘let me know if you need anything’ but you don’t know how to be more specific than ‘I need help’…. So you try to complete your work alone, wanting to prove that you’re worthy.” https://www.linkedin.com/pulse/imagine-sarah-anoke-phd/
- It’s still too early to measure the duration and frequency of long-term complications for a new virus, but early evidence suggests they could be important. https://www.theatlantic.com/health/archive/2020/06/covid-19-coronavirus-longterm-symptoms-months/612679/ https://www.vox.com/2020/5/8/21251899/coronavirus-long-term-effects-symptoms
Nate Silver (@NateSilver538):
Some Q’s I have:
—How many people suffer from long-term complications? —Is the IFR declining, and if so why? —How much of the population is susceptible to COVID-19? Is there cross-immunity from other coronaviruses? —How much do heterogeneities affect the herd immunity threshold?
HCQ should never have received an Emergency Use Authorization, which is too easily conflated with the idea that “FDA says it works.” The original decision was decried by former FDA leaders, and stood in contrast with EMA’s approach. From me in April: https://www.washingtonpost.com/outlook/coronavirus-hydroxychloroquine-trials-research/2020/04/10/fa003ada-7a7a-11ea-a130-df573469f094_story.html
Helen Branswell (@HelenBranswell):
.@US_FDA rescinds emergency use authorizations for hydroxychloroquine, which has not proved to be useful against #Covid19. https://t.co/u1bFGV9Itf